Introduction

The elderly population suffers from the natural process called immunosenescence, which may be related to the high mortality rates it has against the SARS-CoV2 virus, which is why therapies that improve the immune status are required. The combined treatment of the VA-MENGOC-BC® (V-BC) vaccine and the Biomodulina T® (BT) drug could achieve this purpose. This treatment could immunomodulate both the innate and adaptive branches of the immune system simultaneously.

Objective

To determine the effect of BT and V-BC on the immunomodulation of lymphocyte subpopulations in older adults.

Methods

Our study was carried out in 30 apparently healthy Cuban adults over 65 years of age. The study included three groups of 10 subjects per treatment: a combination of both and the monotherapies. Before and 7 days after treatment, 2 mL of peripheral blood was drawn from each subject. Multiparametric flow cytometry was used to identify lymphocyte subpopulations. For the comparison between the groups, point estimates and the confidence intervals of the Odds Ratio were made.

Results

We found that subpopulations of B lymphocytes and natural cytotoxic T (NKT) cells increased only with the administration of BT. Additionally, combination treatments and V-BC did not generate statistically significant immunomodulatory changes in any of the studied lymphocyte subpopulations.

Conclusions

BT presented an immunoenhancing effect on the B and NKT lymphocyte subpopulations of older adults. The three-dose treatment scheme a novel and specific treatment strategy for this formulation. We also were verified that the combined application of V-BC and BT did not have the expected benefits. All these findings suggest that BT administration is a promising approach for immune restoration and to offering protection in elderly patients against COVID-19.

中文翻译：

---

Biomodulina-T® 和 VA-MENGOC-BC® 对老年人淋巴细胞亚群的影响

介绍

老年人口患有称为免疫衰老的自然过程，这可能与其对 SARS-CoV2 病毒的高死亡率有关，这就是为什么需要改善免疫状态的疗法。VA-MENGOC-BC® (V-BC) 疫苗和 Biomodulina T® (BT) 药物的联合治疗可以达到这一目的。这种治疗可以同时对免疫系统的先天性和适应性分支进行免疫调节。

客观的

确定 BT 和 V-BC 对老年人淋巴细胞亚群免疫调节的影响。

方法

我们的研究是在 30 名 65 岁以上、外表健康的古巴成年人中进行的。该研究包括三组，每组 10 名受试者，每次治疗：两者和单一疗法的组合。治疗前和治疗后 7 天，从每个受试者身上抽取 2 mL 外周血。多参数流式细胞术用于鉴定淋巴细胞亚群。对于组间的比较，进行了点估计和比值比的置信区间。

结果

我们发现 B 淋巴细胞和天然细胞毒性 T (NKT) 细胞的亚群仅随着 BT 的施用而增加。此外，联合治疗和 V-BC 并未在任何研究的淋巴细胞亚群中产生统计学上显着的免疫调节变化。

结论

BT 对老年人的 B 和 NKT 淋巴细胞亚群具有免疫增强作用。三剂量治疗方案是该制剂的一种新颖且特异性的治疗策略。我们也验证了 V-BC 和 BT 的联合应用并没有达到预期的效果。所有这些发现表明，BT 给药是一种很有前途的免疫恢复方法，可以为老年患者提供针对 COVID-19 的保护。